Urogen Pharma $URGN Shares Acquired by JPMorgan Chase & Co.

JPMorgan Chase & Co. raised its stake in shares of Urogen Pharma (NASDAQ:URGN) by 36.9% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 534,545 shares of the company’s stock after buying an additional 144,181 shares during the period. JPMorgan Chase & Co. owned approximately 1.14% of Urogen Pharma worth $10,664,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Paradigm Biocapital Advisors LP acquired a new position in Urogen Pharma during the third quarter worth about $84,111,000. Soleus Capital Management L.P. acquired a new stake in Urogen Pharma during the second quarter valued at approximately $29,934,000. SG Americas Securities LLC lifted its stake in Urogen Pharma by 0.7% during the third quarter. SG Americas Securities LLC now owns 1,157,383 shares of the company’s stock valued at $23,090,000 after purchasing an additional 8,302 shares during the last quarter. TCG Crossover Management LLC bought a new stake in Urogen Pharma during the third quarter worth approximately $14,311,000. Finally, Orbimed Advisors LLC boosted its holdings in Urogen Pharma by 44.0% during the third quarter. Orbimed Advisors LLC now owns 689,000 shares of the company’s stock worth $13,746,000 after buying an additional 210,600 shares in the last quarter. 91.29% of the stock is currently owned by institutional investors.

Urogen Pharma Price Performance

URGN stock opened at $17.17 on Friday. The firm has a market capitalization of $835.84 million, a P/E ratio of -5.37 and a beta of 1.34. Urogen Pharma has a 52-week low of $3.42 and a 52-week high of $30.00. The company’s 50 day simple moving average is $19.88 and its 200-day simple moving average is $20.76.

Urogen Pharma (NASDAQ:URGN) last posted its quarterly earnings data on Monday, March 2nd. The company reported ($0.54) EPS for the quarter, topping analysts’ consensus estimates of ($0.66) by $0.12. The firm had revenue of $37.84 million during the quarter, compared to analyst estimates of $39.92 million. Sell-side analysts predict that Urogen Pharma will post -3.12 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

URGN has been the subject of a number of recent research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Urogen Pharma in a research report on Wednesday, January 21st. D. Boral Capital restated a “buy” rating and issued a $33.00 target price on shares of Urogen Pharma in a report on Monday, March 2nd. Finally, Oppenheimer reaffirmed an “outperform” rating on shares of Urogen Pharma in a research report on Monday, March 2nd. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Urogen Pharma presently has a consensus rating of “Moderate Buy” and an average price target of $33.29.

Insider Buying and Selling at Urogen Pharma

In related news, General Counsel Jason Drew Smith sold 7,479 shares of the stock in a transaction dated Tuesday, February 3rd. The stock was sold at an average price of $19.69, for a total value of $147,261.51. Following the completion of the sale, the general counsel directly owned 51,326 shares of the company’s stock, valued at approximately $1,010,608.94. This represents a 12.72% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Mark Schoenberg sold 7,373 shares of the stock in a transaction dated Tuesday, February 3rd. The stock was sold at an average price of $19.69, for a total value of $145,174.37. Following the completion of the sale, the insider directly owned 144,985 shares of the company’s stock, valued at approximately $2,854,754.65. This represents a 4.84% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Company insiders own 4.70% of the company’s stock.

About Urogen Pharma

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.